Long-term Extension Study of Ligelizumab in Food Allergy

Inclusion Criteria:

- Signed informed consent and assent form (where applicable)

- Participants have completed the treatment period in any ligelizumab Phase III
studies in food allergy

- Participants are willing to adhere to the study visits and procedures, including
receiving injections and participating in the oral food challenge

- Participants agree to continue avoiding exposure to allergens (per core study) and
any other foods they are allergic to throughout the study

- Participants are able to safety continue into the study as judged by the
investigator

Exclusion Criteria:

- Development of a severe or life threatening episode of an allergic reaction that
required intubation and/or Intensive Care Unit admission during the core studies

- Development of a serious adverse event which is suspected to be related to the study
treatment judged by the investigator during the core studies

- Development of uncontrolled asthma during the core study that could compromise the
safety of participants judged by the investigator

- Development of clinically significant cardiovascular, neurological, and or
psychiatric conditions during the core study that could interfere with or compromise
the safety of the participants, interfere with evaluation or interpretation of the
study results or preclude completion of the study judged by the investigator

- Participants who failed to comply with the protocol requirements and procedures
duringthe core study, and in the Investigator's opinion they should not participate
in this extension study

- Platelets <75,000/ul at end of treatment of the core study

Other protocol defined inclusion/exclusion criteria may apply